A5060578315- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Neuroendocrine Tumor Research Advances
- Uterine Myomas and Treatments
- Lung Cancer Research Studies
- Intraperitoneal and Appendiceal Malignancies
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Endometriosis Research and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cervical Cancer and HPV Research
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Management of metastatic bone disease
- Radiation Dose and Imaging
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Pituitary Gland Disorders and Treatments
- Pancreatic and Hepatic Oncology Research
- Bone health and treatments
- Medical Imaging and Pathology Studies
- Shoulder Injury and Treatment
- Gestational Trophoblastic Disease Studies
Gartnavel General Hospital
2010-2023
Beatson West of Scotland Cancer Centre
2012-2023
Clinical Trial Investigators
2021
NHS Greater Glasgow and Clyde
2015-2021
Vall d'Hebron Hospital Universitari
2016
Vall d'Hebron Institute of Oncology
2016
Vilnius University
2016
Institut Gustave Roussy
2016
University of Turin
2015
Shrewsbury and Telford Hospital NHS Trust
2015
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform framework for NENs at any anatomical location may reduce inconsistencies contradictions among the various in use. suggested here is intended to allow pathologists clinicians manage their patients with consistently, while acknowledging organ-specific differences criteria, tumor biology, prognostic factors. based on a consensus conference held International...
Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap.
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis management of digestive neuroendocrine carcinoma, based recent developments study results. These recommendations aim to pave road for more standardized care our patients resulting in improved outcomes. Prognosis is generally poor NEC, most are advanced at median survival metastatic disease 11-12 months. Surgery can be benefit localized after extensive...
The EORTC-55994 trial compared neoadjuvant chemotherapy (NACT) followed by radical surgery with concomitant chemoradiation (CCRT) in patients Stage IB2-IIB cervical cancer. This took almost 12 years to recruit 626 a median follow-up of 8.7 years.
5503 Background: Conflicting evidence on the value of neoadjuvant chemotherapy followed by surgery compared to concomitant chemoradiation in Stage IB2-IIB cervical carcinoma led this multinational multicenter trial. As trial is approaching completion its follow-up, preliminary results are presented. Methods: Between May 2002 and June 2014 a total 620 patients with FIGO stage Ib2-IIb were randomized between (NACTS, arm 1, N=311) standard chemoradiotherapy (CCRT, 2, N=309) . In radical...
Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules etirinotecan in patients platinum-resistant/refractory ovarian carcinoma.
Objective Advanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant tissue high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as therapeutic target in patients with cancer. Methods This phase 2, multicenter, international, open-label, randomized (1:1), 2-arm the inhibitor oral irosustat 40 mg/d versus megestrol acetate 160 women advanced/metastatic estrogen receptor–positive primary end point proportion without progression death 6...
More than 50% of all gynecologic tumors can be classified as rare (defined an incidence ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis treatment. In contrast almost other common solid tumors, the treatment (RGT) is often based on expert opinion, retrospective studies, or extrapolation from tumor sites with similar histology, leading difficulty in developing guidelines for clinical practice. Currently, cancer research, due distinct scientific technological...